Roche Holding licensed a new weight-loss drug from Zealand Pharma, bolstering the drugmaker’s effort to get into a hot market dominated by Novo Nordisk and Eli Lilly & Co. Read More
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
Related Posts
Amazon’s bestselling routers, which power internet in most U.S. homes, could soon be banned over national-security concerns
Microsoft says TP-Link routers are vulnerable to Chinese hackers. Read More
China’s war games near Taiwan could be used to conceal attack, US says
Unlock the White House Watch newsletter for free Your guide to what the 2024 US election means for Washington and…
Adobe’s CFO: Agentic AI is a ‘natural evolution’ for the company
Dan Durn explains why 2025 is the year AI will be a game-changer for companies. Read More